ReachRxResearch
Home
Research
Sign Up
Trends in Metabolic and Bariatric Surgery Procedure Volume Recorded in MBSAQIP, 2015–2024
Back to Research Hub
  1. Home
  2. Research Hub
  3. Trends in Metabolic and Bariatric Surger…

Trends in Metabolic and Bariatric Surgery Procedure Volume Recorded in MBSAQIP, 2015–2024

Obesity Surgery·September 29Open Access
SurgeryPractice changingSevere ObesityRepeated Cross-Sectional StudyBariatric SurgeryRoux-En-Y Gastric BypassSleeve GastrectomyAdolescentAdultMixed

Summary

View source

What was studied

Trends in metabolic and bariatric surgery (MBS) procedure volume in the U.S. from 2015 to 2024 using MBSAQIP registry data, analyzed separately for adults (≥19 years) and adolescents (10–18 years) with a prespecified change point at 2022.

Key findings

Among 1,970,021 MBS patients, adult volume grew ~3.94%/year from 2015–2022 (peak 229,826 in 2022) then fell ~11.29%/year through 2024 (176,915 procedures; p<0.001); adolescent volume rose ~10.53%/year through 2022 and continued rising without a significant post-2022 decline (p=0.98). Sleeve gastrectomy was most common (61.8%), followed by Roux-en-Y gastric bypass (27.7%).

Study limitations

MBSAQIP captures only accredited participating centers, not all U.S. MBS procedures; the number of participating centers changed over time and hospital-level identifiers are unavailable. No eligible-population denominator exists, preventing per-capita utilization estimates. Key potential confounders—GLP-1 RA use, insurance changes, referral patterns—are not captured in the registry.

Clinical implications

Adult bariatric surgery volume has declined sharply since 2022, possibly related to the rise of GLP-1-based therapies, though causation cannot be established. Clinicians should monitor whether this trend persists, as it may signal shifting patient preferences or access barriers affecting who reaches surgical care.

Caveats

  • MBSAQIP only covers accredited centers, so findings may undercount total U.S. MBS volume and are not fully nationally representative
  • Racial and ethnic utilization trends are presented without eligible-population denominators, so conclusions about equity in access should be drawn cautiously
  • The post-2022 adult volume decline is temporally correlated with GLP-1 RA expansion, but this registry cannot establish causation; multiple other factors (insurance, capacity, patient preference, COVID aftereffects, changes in MBSAQIP participation) may have contributed

Related Questions

Explore related topics

What is the impact of GLP-1 receptor agonists like semaglutide and tirzepatide on bariatric surgery referral rates?How do outcomes compare between metabolic and bariatric surgery versus GLP-1-based pharmacotherapy for severe obesity?What are the trends in adolescent bariatric surgery utilization and access in the United States?

Publication Details

Year
2026
Journal
Obesity Surgery
Sample Size
n=1,970,021
Source
View article
Keep scrolling
More content below.
Up Next